Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Cash from Investing Activities data on file, last reported at $40.2 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 49.08% year-over-year to $40.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $367.2 million (down 6.62% YoY) and the FY2025 annual result came in at $377.2 million, up 3.78% from the prior year.
• Cash from Investing Activities retreated to $40.2 million in Q2 2026, from $141.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $250.8 million in Q3 2024 to a low of -$49.2 million in Q4 2024.
• A 5-year average of $78.1 million and a median of $82.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 537.49% in 2024, down 151.47% in 2024.
• Tracing AGIO's Cash from Investing Activities over 5 years: stood at $83.0 million in 2022, then climbed by 15.14% to $95.5 million in 2023, then sank by 151.47% to -$49.2 million in 2024, then surged by 283.24% to $90.1 million in 2025, then sank by 55.36% to $40.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $40.2 million (Q2 2026), $141.3 million (Q1 2026), and $90.1 million (Q4 2025), per Business Quant data.